Kuang Hu - Consultant Ophthalmic Surgeon Glaucoma Treatment & Cataract Surgery Excellence in eye care is the focus of the team led by Mr Kuang Hu, London-based Moorfields Consultant Ophthalmic Surgeon, who specialises in Glaucoma and Cataracts. Assessment of your eye condition will include a thorough examination and any necessary special tests, many of which can be performed conveniently in-house. A wide range of treatments is available, including minimally-invasive day-case surgical procedures. Focussed on Excellence in Eye Care Mr Hu believes in providing a high-quality service, good value for money, and convenience. So, your first consultation with him at Infinity Eye Clinic in Harley Street comes with a Satisfaction Guarantee and Price Promise. Infinity Eye Clinic can also arrange a car and driver to bring you to and from your home or workplace – at our expense if you are local. Value and Convenience But that’s not all. Mr Hu offers consultations at weekends to fit in with busy schedules. With transparent pricing of his services, there’ll be no nasty surprises when it comes to fees. And you can book consultations without the need for health insurance.

Connect with Us Our team is always happy to hear from you, so connect via telephone, email or social media. Latest updates - DeepMind Health | Moorfields Eye Hospital NHS Foundation Trust Latest updates - DeepMind Health OCT scan 20 September 2016, DeepMind Health patient engagment event DeepMind Health held their first large-scale patient and public involvement event on 20th September 2016, bringing together a diverse group of patients and carers to hear about the work DeepMind Health are doing and to help decide on the best way to involve service users going forward. Over 130 patients, carers and members of the public were in attendance with many more watching the livestream. Moorfields patient Elaine Manna took to the stage to tell her story of how age-related macular degeneration (AMD) has affected her and why she has been inspired by the research project between Moorfields and DeepMind Health. Mr Pearse Keane, consultant ophthalmologist at Moorfields Eye Hospital, also explained how the research partnership came about and the hope that this work will eventually help eye health professionals to make faster and more accurate diagnoses of the commonest eye conditions. The live stream of the event is available to watch below.

4 July 2016, We are excited to announce a new medical research partnership with DeepMind Health. A new medical research partnership that could revolutionise the way professionals carry out eye tests and lead to earlier detection of common eye diseases has been launched in London. With the number of people suffering from sight loss in the UK predicted to double by 2050, Moorfields Eye Hospital NHS Foundation Trust and DeepMind Health will explore how cutting edge technologies can help medical research into eye diseases, including age-related macular degeneration and sight loss as a result of diabetes. The partnership brings together leading NHS eye health professionals with some of the UK’s top technologists at DeepMind, which specialises in using machine learning technologies to solve some of the world’s most difficult problems. As part of the research project between the Moorfields Eye Hospital and DeepMind, machine learning will be applied to one million anonymous eye scans, to look for early signs of eye conditions that humans might miss. Two million people are living with sight loss in the UK, of whom around 360,000 are registered as blind or partially sighted. With the right treatment at the right time, many cases are preventable.

For example, it is estimated that up to 98% of sight loss resulting from diabetes can be prevented by early detection and treatment. Both Moorfields Eye Hospital and DeepMind Health hope that this work will eventually help eye health professionals to make faster and more accurate diagnoses, leading to better treatment for patients living with eye conditions. Professor Sir Peng Tee Khaw, Director of the National Institute for Health Research Biomedical Research Centre in Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology, said: "Our research with DeepMind has the potential to revolutionise the way professionals carry out eye tests and could lead to earlier detection and treatment of common eye diseases such as age-related macular degeneration. With sight loss predicted to double by the year 2050 it is vital we explore the use of cutting-edge technology to prevent eye disease." Mustafa Suleyman, co-founder of DeepMind, said: “We set up DeepMind because we wanted to use AI to help solve some of society's biggest challenges, and diabetic retinopathy is the fastest growing cause of blindness worldwide. There are more than 350m sufferers across the planet. I'm really excited to announce this collaboration with leading researchers at Moorfields.

Detecting eye diseases as early as possible gives patients the best possible chance of getting the right treatments. I really believe that one day this work will be a great benefit to patients across the NHS. We are proud of our NHS, and this is one of the ways I think we can help nurses and doctors continue to provide world-class care.” Dr Dolores Conroy, Director of Research at Fight for Sight welcomes this partnership and comments: “We are really excited about this collaboration and the potential of machine learning to analyse the thousands of retinal scans taken each week in the NHS allowing eye health professionals to make faster, more accurate diagnoses and more timely treatments thus preventing sight loss. In the longer term this technology could provide important insights into disease mechanisms in wet AMD and diabetic retinopathy”. Cathy Yelf, Chief Executive of the Macular Society, said: "This is an exciting development towards early detection of eye disease and finding a cure for conditions including age-related macular degeneration (AMD). AMD is a devastating condition and delays due to pressure on eye clinics have resulted in some people suffering unnecessary sight loss.

This technology could ease that pressure if it can accurately diagnose conditions such as wet AMD resulting in urgent referrals for only those that need them.” Clara Eaglen, RNIB Eye Health Campaigns Manager, said: "AI technology that can check retinal scans and detect eye disease at a much earlier stage could play a big role in tackling avoidable sight loss. In many cases, once sight is lost it cannot be restored, so earlier detection that leads to rapid treatment will be hugely beneficial. We look forward to seeing the results of the work as the research progresses." For media enquiries, please contact the DeepMind Press Office on deepmind-press@google.com or emilyclarke@google.com or call 07734 967284 or the Moorfields Eye Hospital Press Office on press.office@moorfields.nhs.uk or call 020 7566 2628. For out of hours enquiries please call 020 7253 3411 who will contact the on call press officer. Up to 50% of people with proliferative diabetic retinopathy who do not receive timely treatment will become legally blind within five years.

Up to 98% of severe vision loss from diabetic retinopathy can be prevented by early detection and treatment. By efficiently analysing the large number of scans and images taken of the eye every year, a machine learning algorithm could ensure the right patients in need of treatment are seen at the right time by the right clinician. Age-related macular degeneration (AMD) will affect an estimated 2.5 million adults by 2020 in the UK alone. Around 15% of early cases of AMD progress to the more serious form of wet AMD, which can be difficult for a clinician to predict. Machine learning has an opportunity to filter through the huge quantity of information available from scans of the eye, and potentially recognise subtle features which predict the onset of wet AMD. This early warning system could initiate faster intervention and the prevention of patient eye deterioration in the future. Sight loss in the UK. Two million people in the UK are living with sight loss that has a significant impact on their daily lives (Access Economics, 2009). The leading causes of sight loss in the UK are uncorrected refractive error, age-related macular degeneration, cataract, glaucoma and diabetic retinopathy.

This figure includes people who are registered as blind or partially sighted and those whose sight is just better than the levels which qualify for registration. DeepMind has access to approximately one million anonymous digital eye scans, along with some related anonymous information about eye condition and disease management. This means it’s not possible to identify any individual patients from the scans. They’re also historic scans, meaning that while the results of our research may be used to improve future care, they won’t affect the care any patient receives today. The data used in this research is not personally identifiable. When research is working with such data, which is anonymous with no way for researchers to identify individual patients, explicit consent from patients for their data to be used in this way is not required. For more information please refer to the ICO code of conduct . Moorfields Eye Hospital NHS Foundation Trust is one of the world’s leading eye hospitals, providing expertise in clinical care, research and education. We have provided excellence in eye care for more than 200 years and we continue to be at the forefront of new breakthroughs and developments. We are an integral part of one of the UK’s first academic health science centres, UCL Partners, and now we are part of one of the first science health networks.

We were one of the first organisations to become an NHS foundation trust in 2004. For further information, please visit . NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was established in April 2007 and awarded a second five-year term by the NIHR from April 2012. Its purpose is to conduct 'translational research' that is designed to take advances in basic medical research from the laboratory to the clinic, enabling patients to benefit more quickly from new scientific breakthroughs. Our centre is currently one of 11 biomedical research centres that were awarded in 2012 to NHS/university partnerships with an outstanding international reputation for medical research and expertise, and experience of translating that research into the clinical setting. For further information, please visit . Founded in London in 2010, DeepMind was supported by some of the most iconic tech entrepreneurs and investors of the past decade, prior to being acquired by Google in early 2014 in their largest European acquisition to date. Its world-class team consists of many renowned experts in their respective fields, including but not limited to deep neural networks, reinforcement learning and systems neuroscience-inspired models.

DeepMind Health was launched in February 2016 to work with talented clinicians in the NHS and other health services to develop and use technology in the provision of world-class care. For further information please visit . Fight for Sight is the leading UK charity dedicated to funding pioneering research to prevent sight loss and treat eye disease. Fight for Sight is funding research at leading universities and hospitals throughout the UK. Our current research programme is focusing on preventing and treating age-related macular degeneration, diabetic retinopathy, glaucoma, cataract and corneal disease. We are also funding research into the causes of childhood blindness and a large number of rare eye diseases. For further information, please visit or call 020 7264 3900. The Macular Society is the national charity for anyone affected by central vision loss. Our 22,000 members make us the biggest patient group in the sight loss sector and the voice of people with macular conditions. We provide free information and support to improve lives and ensure no one has to face macular disease alone. We have 300 Macular Society support group around the UK and beyond. We fund research so that one day we can overcome macular disease.

For further information, please visit . RNIB. Every 15 minutes, someone in the UK begins to lose their sight. We are the Royal National Institute of Blind People (RNIB) and we're here for everyone affected by sight loss - that's over 2 million people in the UK. If you, or someone you know, has a sight problem, RNIB can help. Call the RNIB Helpline on 0303 123 9999 or visit . Moorfields Eye Hospital University College Dublin, Ireland (1996-2002 and 2003-2004) Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, USA (2000) St.

Vincent’s University Hospital, Dublin, Ireland (2002-2003) Cork University Hospital, Cork, Ireland (2004-2006) Waterford Regional Hospital, Waterford, Ireland (2006-2007) Doheny Eye Institute, UCLA, Los Angeles, USA (2007-2009) West Midlands Deanery, Birmingham and Hereford, UK (2009-2010) Moorfields Eye Hospital (2010-2015) Research interest / experience: Dr Keane specialises in the diagnosis and management of retinal disease, with a particular interest in age-related macular degeneration (AMD) and other macular diseases. He also carries out an extensive programme of research at UCL, with a particular expertise in retinal imaging using optical coherence tomography (OCT). In April 2015, he was ranked no.

4 on a worldwide ranking of ophthalmologists under 40, published in "the Ophthalmologist” journal ( In January 2015, he was awarded a prestigious "Clinician Scientist” award from the National Institute of Health Research (NIHR) in the United Kingdom - the first ophthalmologist in the UK to receive such an award. His remit from this award is to explore the potential of new medical technologies and innovation in the treatment of visual impairment and blindness, with a particular focus on ophthalmic imaging. He has published extensively, with >100 articles in peer-reviewed literature. He is also the associate editor of Scientific Reports (part of the Nature publishing group) and BMC Ophthalmology.

Practice manager contact details: First UK patient receives stem cell treatment to cure loss of vision | Science | The Guardian Stem cells First UK patient receives stem cell treatment to cure loss of vision Experimental transplant uses eye cells grown in a lab and if successful could be used to treat hundreds of thousands of macular degeneration sufferers in UK Tuesday 29 September 2015 04.10 EDT First published on Monday 28 September 2015 19.01 EDT Close This article is 1 year old A patient has become the first in the UK to receive an experimental stem cell treatment that has the potential to save the sight of hundreds of thousands of Britons. By December, doctors will know whether the woman, who has age-related macular degeneration, has regained her sight after a successful operation at Moorfields Eye Hospital in London last month. Over 18 months, 10 patients will undergo the treatment. The transplant involves eye cells, called retinal pigment epithelium, derived from stem cells and grown in the lab to form a patch that can be placed behind the retina during surgery. Stem cell therapy success in treatment of sight loss from macular degeneration Read more The potential is huge.

Although the first patients have the ‘wet’ form of macular degeneration, the doctors believe it might also eventually work for those who have the ‘dry’ form, who are the vast majority of the UK’s 700,000 sufferers. The surgery is an exciting moment for the 10-year-old London Project to Cure Blindness , a collaboration between the hospital, the UCL Institute of Ophthalmology and the National Institute for Health Research, which was formed to find a cure for wet age-related macular degeneration, the more serious but less common form of the disease. Prof Pete Coffey of UCL, one of the founders of the London Project, said he would not be working on the new treatment if he did not believe it would work. He hopes it could become a routine procedure for people afflicted by vision loss, which is as common a problem among older people as dementia. “It does involve an operation, but we’re trying to make it as straightforward as a cataract operation,” he said. “It will probably take 45 minutes to an hour. We could treat a substantial number of those patients.” First they have to get approval. The trial is not just about safety, but also efficacy.

There will be a regulatory review after the first few transplants to ensure all is going well. The group of patients chosen have the wet form of the disease and experienced sudden loss of vision within about six weeks. The support cells in the eye, which get rid of daily debris and allow the seeing part to function have died. “There is a possibility of restoring their vision,” said Coffey. The aim of the transplant is to restore the support cells so the seeing part of the eye is not affected by what would become an increasingly toxic environment, causing deterioration and serious vision loss. The surgery is being performed by retinal surgeon Prof Lyndon Da Cruz from Moorfields, who is also a co-founder of the London Project. The team chose people with this dramatic vision loss to see whether the experimental stem cell therapy would reverse the loss of vision. But in those with dry macular degeneration, said Coffey, the process is far slower, which would mean doctors could choose the time to intervene – if the treatment works. Helping people to regain their sight has long been one of the most hopeful prospects for stem cell transplantation.

Other research groups have been trialling the use of stem cells in people with Stargardt’s disease, which destroys the vision at a much earlier age. Stem cells have moved from the drawing board into human trials with incredible speed, scientists say. The first embryonic stem cell was derived in 1989. Using them in eyes was always going to have a big advantage over other prospects, because it is possible to transplant them without an all-out attack by the immune system, as would happen in other parts of the body. Most people who have any sort of transplant have to take drugs that suppress the immune system for the rest of their lives. Just like conventional medicines, stem cell therapies will very likely have to be developed and marketed by large commercial concerns. The London Project has the US drug company Pfizer on board. Neoh exhibits at the Moorfields Eye Hospital with Vandal Therapy | Inspiring City Random Wanderings around London looking at Street Art and other things Neoh exhibits at the Moorfields Eye Hospital with Vandal Therapy by inspiringcity Street artist Neoh who by day works as an art therapist with the Outsider Gallery has chosen a corridor of one of London’s best known hospitals to exhibit his first solo show.

‘Vandal Therapy’ is the continuation of a body of work Neoh has been painting on the streets for many years now. A campaigner on mental health issues his abstract work evokes movement and jumps out at you with it’s bright colours and raw energy. The choice of Moorfields Eye Hospital is in keeping with the artists support of those accessing healthcare. The Moorfields Eye Hospital NHS Trust has long been a supporter of the visual arts and you can see this as you walk around the place, art takes pride of place on many of the walls. Work on the walls of the Moorfields Eye Hospital It may seem an unusual place to exhibit but according to Moorfields the aim is to highlight the fact that many people who are visually impaired still appreciate and are able to be be active within the visual arts. It’s a combination that works, Neoh’s art is primarily around issues to do with mental health and is the output of his art therapy work. The fact that it now hangs on the walls of a hospital for people with sight problems means that the the art can be shared and experienced in a different context but yet still act as therapy for others.

The show itself was unique for another reason in that when it opened it was the first hospital to take part in the monthly first Thursday series of art shows which take over the hipster heart of Shoreditch and the East End every month. Hipster the eye hospital is not but fair play to them for being open to opening their doors for this sort of thing. Neoh painting his ballerinas at an open studio in Hackney Wick Vandal Therapy is an exploration of Neoh’s state of mind through a series of expressively painted and vibrant self portraits. According to Moorfields “the fact that Neoh’s work is both visually appealing, and at the same time deals with difficult topics like mental health: it adds another dimension to it when set in a space like Moorfields. Losing one’s sight can be devastating, both mentally and physically. But people rarely talk about the emotional impact of sight loss.” Normally associated with his work on the street, Neoh is probably best known for his series of ballerinas which can be seen dotted around areas such as Hackney Wick as well as Shoreditch. Those too evoke movement but their faces are often distorted.

The show contains a series of self portraits The show at the Moorfields is one of a number the Moorfields Art Committee plan to put on this year and it seems appropriate that this from Neoh is the first. According to Neoh, “I’m really excited that my first solo show will be at Moorfields. It’s rare that the output of therapy is exhibited, but I believe that the arts can significantly contribute to peoples’ wellbeing, mental health and recovery.” Vandal Therapy can be found in the pharmacy/optometry corridor at Moorfields main hospital on City Road. Enter through the main entrance and follow the blue line around and look out for the show in the corridor. Vandal Therapy by Neoh Dr. Avinash Gurbaxani | Moorfields Eye Hospital Abu Dhabi MB BS, DOMS, FRCS (Ed) (Ophth) Consultant Ophthalmic Surgeon in Uveitis and Medical Retinal Diseases Dr. Gurbaxani specialises in the assessment and management of uveitis and inflammatory eye disease (uveitis, infectious diseases, autoimmune diseases of the eye) as well as medical retinal disease, such as diabetes, macular degeneration and retinal vascular disease.

He has broad experience in the diagnosis and management of complex inflammatory eye diseases, including the use of immunosuppression, as well as in treating retinal disease. Dr Gurbaxani is also skilled in managing complex cataract surgery associated with these diseases. Dr. Gurbaxani trained in ophthalmology in Oxford and London, working at The Oxford Eye Hospital in Oxford, Kings College Hospital, St. Thomas’ Hospital and Moorfields Eye Hospital in London. He has worked at the prestigious Medical Eye Unit in London as well as completing a Uveitis Fellowship and Medical Retina Fellowship at Moorfields London and the Sydney Eye Hospital in Australia, before returning to Moorfields London as a locum consultant. Dr Gurbaxani is experienced in initiating research projects and running clinical trials, and has regularly published and presented papers at national and international conferences. He is a member of several professional bodies including the Royal College of Ophthalmologists (RCOphth), Royal College of Surgeons of Edinburgh (RCS)(Ed), American Academy of Ophthalmology (AAO). Click here to read more on Cataract Surgery. Click here to read more on Macular Degeneration. Click here to read more on Common Eye Conditions.

Stem cell trial for Stargardt's macular dystrophy - Health News - NHS Choices Friday September 23 2011 Stem cells can develop into any type of body cell “UK medics lead Europe's first embryonic stem cell trial,” reported BBC News. It said that doctors at Moorfields Eye Hospital in London have been “given the go-ahead” to carry out Europe's first clinical trial using human embryonic stem cells (cells from early stage embryos that have the potential to develop into any type of body cell). In the trial in London, retinal cells derived from embryonic stem cells will be injected into the retina of people with Stargardt's macular dystrophy, which is an inherited condition that causes progressive, and eventually total, loss of central vision. This early trial, which is likely to start within the next few months, is aimed at testing the safety of the treatment in humans. It may be some time before we know whether it works. If the results indicate that there are no serious side effects, further trials in larger numbers of people will give a better idea of how well it works for people at different stages of the disease.

The researchers hope that the treatment may also work for other eye conditions, such as age-related macular degeneration, but this is only a theory at present and further research will be needed to investigate this. What is Stargardt’s disease? Stargardt’s disease or Stargardt’s macular dystrophy is the most common form of inherited juvenile macular degeneration, affecting around one in 10,000 children. To develop the condition, people need to inherit a copy of the ‘mutant’ Stargardt's gene from both parents. The parents themselves will not have been affected if they carry only one copy of the gene. The condition affects the area of the retina called the macular, which enables us to see directly in front of us. This part of the retina is needed for everyday activities such as reading and writing. The two main changes that occur on the retina are an oval lesion around the macular area, which is referred to as having a ‘beaten bronze’ appearance and which causes gradual deterioration in the function of the macular cells over time. The second change that is distinctive of the condition is the appearance of yellowish flecks around the lesion. These are lipid (fat) deposits.

The changes to the macular occur gradually, so that most affected individuals will first start to notice visual problems as an adolescent. Patients may be advised to avoid exposure to bright light and to wear UV-protective sunglasses to try to slow progression of the disease. There are currently no treatments to prevent the visual loss. Most sufferers will become legally blind (less than 6/60 vision) in adulthood due to the loss of their central vision. What are embryonic stem cells? Embryonic stem cells are unique in that they have the potential to develop (differentiate) into any type of adult body cell. Most embryonic stem cells are taken from embryos that have been fertilised in vitro in the laboratory (IVF), and the cells are then cultured in the laboratory, remaining in their undifferentiated form unless researchers put them under conditions that will allow them to change into different cell types. Under laboratory conditions it has been possible to develop retinal cells from these cells, which is a significant advance and could potentially be translated into new treatments for patients who have otherwise untreatable visual loss due to damage to their own retinal cells.

As a first step, the researchers would need to test the safety of transplanting retinal cells in a small number of affected individuals. The newspapers report that the team at Moorfields Eye Hospital has been given approval to go ahead with the trial by the Medicines and Healthcare Products Regulatory Agency (MHRA). This is the UK governing body responsible for ensuring public safety by monitoring the safety of all medical treatments and procedures. The technique was originally developed by the US company Advanced Cell Technology (ACT), which started similar trials in the United States from November 2010. How will the trial be performed? The trials are due to start in the next few months, and will be led by Professor James Bainbridge, one of Moorfields’ retinal surgeons, at the National Institute for Health Research (NIHR) biomedical research centre for ophthalmology, based at Moorfields and the University College London (UCL) Institute of Ophthalmology. During an operation lasting up to an hour, the stem-cell-derived retinal cells will be transplanted into adults with severe sight impairment as a result of Stargardt’s disease, but who are otherwise healthy. What is the purpose of the trial?

At this current early stage in development of the technology, the trial has one principal aim - to see whether transplanting retinal cells into people with Stargardt’s disease is safe. The trial is important because there are currently no treatments available for Stargardt’s disease. Therefore, if this treatment is successful it could have huge potential and have a life-changing effect for affected individuals. When will we know if it has been successful? The potential for this technique to improve vision will not be known for a long time. The few people who are treated by the procedure in this initial trial will need to be followed up for some time to assess their visual change and any adverse effects. However, to test the efficacy of the technique thoroughly will require further trials with much larger numbers of people. Such trials may go ahead if this first trial demonstrates the technique’s safety. The current trial is specifically related to people with Stargardt’s disease. It is hoped that in the future the technique could be developed and possibly used to treat other blinding disorders of the retina, such as age-related macular degeneration (AMD) , which is the most common cause of age-related visual loss.

However, it is too early to speculate on other potential uses for the technique at its current stage. Analysis by Arnott Eye Arnott Eye 22A Harley Street, London W1G 9BP Appointments: 020 7580 1074 "Without any doubt I would recommend Arnott Eye Associates to my friends and anyone who was willing to listen!"... Read More You are here Consultants Richard Packard MD DO FRCS FRCOphth Richard Packard has been director of Arnott Eye Associates, the internationally recognised centre for ophthalmic excellence, since the retirement of Eric Arnott in 1999. He trained at the Middlesex Hospital, the Hospital for Sick Children Great Ormond Street, the National Hospital for Nervous Diseases and Moorfields Eye Hospital. In 1979 as Senior Registrar at Charing Cross Hospital working under Eric Arnott he first started to perform minimally invasive phacoemulsification surgery for the removal of cataract. It had been Eric Arnott who introduced phaco to Europe in 1973 but very few people there were doing this technique routinely until the late 1980s.

Richard Packard in 1981 published the first description in the medical literature of the use of a folded soft lens in cataract surgery. Since then he has continued to teach phaco techniques as well as being involved in the development of new intraocular lenses, phaco machines and other instrumentation. He has lectured in over 50 countries and is currently involved with the move to micro-incisional cataract surgery. He is senior surgeon at the renowned Prince Charles Eye Unit in Windsor from where most of his research in cataract and lens surgery has emanated. He was a board member of the European Society of Cataract and Refractive Surgeons from 1999-2007, member of the Cataract Clinical Committee of American Society of Cataract and Refractive Surgery from 2004-2008 and is now on their Programme Committee. He has chaired the ESCRS Video Competition Judging Panel since 2000. He is on the Education Committee of ESCRS and runs the Cataract Surgery Didactic Teaching Course.

He is on the peer review panel for the Journal of Cataract and Refractive Surgery, Eye, the British Journal of Ophthalmology and the Asia Pacific Journal of Ophthalmology and regularly contributes to ophthalmic journals. He is currently Chairman of the Association of Ophthalmologists of the UK and deputy chairman of the Federation of Independent Practitioner Organisations. This last is an overarching body that has most of the professional medical and surgical organisations as members and is involved in healthcare in the independent sector Richard Bowman MA MD FRCOphth Richard Bowman is a Consultant Ophthalmologist who specialises in paediatric ophthalmology including cataract, child and adult strabismus (squint/lazy eye) and neuro-ophthalmology (child and adult). He currently works as a Consultant at Great Ormond Street NHS Foundation Trust and Barts Health Whipps Cross NHS Trust. He is also an Honorary Consultant at Moorfields Eye Hospital, an Honorary senior lecturer at the Institute of Child Health and a senior lecturer at the London School of Hygiene and Tropical Medicine. He studied at Cambridge University and trained as a specialist Registrar at the world-renowned Moorfields Eye Hospital.

He spent almost a decade developing eye services in Tanzania, where he gained unique opportunities for high volume cataract surgery in children and seeks to continue to improve the evidence for eye services both in the developing and in the developed world. He has a strong presence at national and international meetings, having published over 50 papers in international journals and 5 book chapters. He is a member of the paediatric subcommittee of the Royal College of Ophthalmologists. Melanie Corbett MD, FRCS, FRCOphth Miss Corbett is a consultant at The Western Eye Hospital, which is part of Imperial College NHS Trust. She specialises in Corneal and Anterior Segment surgery, which includes surgery of the ocular surface, complex cataract and transplantation. She is also responsible for emergency cases including injuries and severe infections. She provides expertise in medical contact lens fitting for many corneal conditions including keratoconus. Miss Corbett qualified from The Royal London Hospital in 1987 and undertook her ophthalmic training Oxford, St Thomas's, Kings College and Moorfields Eye Hospitals. This included subspecialty fellowship training in cornea and complex cataract. She took up her consultant post in 1999.

Miss Corbett has always been very interested in research and new developments, and has published over 60 scientific articles. She received a University of London Award to spend three years in a dedicated research post studying wound healing in the cornea, resulting in an MD degree. Her book "Corneal Topography - principles and applications" addresses the measurement of corneal shape. Miss Corbett also has major roles in training and education, both locally and nationally. She has particular interests in surgical training and trainee development within her own unit. As a Training Programme Director she has responsibility for the delivery and quality assurance of training within the London Deanery. For The Royal College of Ophthalmologists (RCOphth) she sits on the Education and Curriculum Committees. She is the national lead for Training the Trainers, and is extending the programme overseas. In the past she was President of the Medical Contact Lens and Ocular Surface Association (MCLOSA), and hosted the European Medical Contact Lens Conference. She is currently the elected Regional Representative for the Council of the Royal College of Ophthalmologists, and is on the Executive Committee.

Rhodri Daniel BSc(Hons), FRCS, FRCOphth, DO Rhodri Daniel was appointed as Consultant Ophthalmologist to the Primary Care and Accident & Emergency service of Moorfields Eye Hospital, NHS Trust, in January 1993. He had previously completed vocational training in General Practice in the North East Thames Region (Whipps Cross and Wanstead Vocational Training scheme) having designed his own programme to incorporate residencies in Ophthalmology at St Thomas' Hospital, The Royal London Hospital and Moorfields High Holborn. Whilst completing his training in Ophthalmology at Moorfields City Road he obtained the status of Fellow to the Primary Care clinic which was a new and innovative method of delivering high volume new patient services which received commendation from Sir Bernard Tomlinson when he was considering Moorfields for NHS Trust status. He subsequently assisted the Trust management as a Service Director for the Accident & Emergency department for over ten years. He continued in post as a Consultant in Primary Care and Accident & Emergency with an active role in developing the Outreach Programme and has worked at two-thirds of the Moorfields outreach venues, particularly in north Thames and recently beyond the M25.

He has an interest in Medico-Legal practice and is a Tier 1 trained Expert Witness dealing with all aspects of Medico-Legal practice in relationship to general Ophthalmology with an approximately thirty percent defence, thirty percent claimant and forty percent joint instruction or alternative dispute resolution profile. He has published in the field of general Ophthalmology, Ophthalmic education and continues to teach under-graduates and post-graduates at Moorfields City Road. For twenty years he has co-ordinated, chaired and delivered the General Practitioners' Teaching Course held annually at the Institute of Child Health, London. Avi Kulkarni BSc, MBBS, FRCSEd(Ophth) Mr Kulkarni is a substantive NHS consultant ophthalmic surgeon at King's College Hospital in London, where he is Clinical Lead for Ophthalmology and lead glaucoma consultant. After training in ophthalmology in London, Mr. Kulkarni subspecialized in the management of glaucoma and complex, glaucoma-related cataract surgery during clinical glaucoma fellowships at King's College & St. Thomas's Hospitals, and Moorfields Eye Hospital.

He was subsequently appointed to develop and run the glaucoma service at King's College Hospital, a prestigious London university teaching hospital, which is one of the founder member institutions of King's Health Partners, a pioneering UK Academic Health Science Centre. Mr. Kulkarni is the principal glaucoma specialist at the Arnott Eye Associates and offers a comprehensive glaucoma service, including glaucoma screening, glaucoma monitoring, glaucoma Laser treatments, and advanced, cutting edge glaucoma surgery. Vickie Lee MA FRCOphth Vickie Lee is a Consultant Ophthalmic and Oculoplastuc Surgeon (eyelid specialist) at the Central Middlesex Hospital, London, an Honorary Consultant Ophthalmic Surgeon at the Western Eye Hospital and an Honorary Senior Lecturer at the Imperial College School of Medicine. She qualified from Cambridge University and St Bartholomew's Hospital Medical School and this was followed by many years of ophthalmology training at the Western Eye Hospital, St Bartholomew's Hospital and Moorfields Eye Hospital in London. She then undertook further specialist training on ophthalmic plastic and reconstructive surgery.

In 2002 she was appointed Consultant Ophthalmic and Oculoplastic Surgeon at the Central Middlesex Hospital in London. Miss Lee is a Fellow of the Royal College of Ophthalmologists, a Founder Member of the British Ophthalmic Plastic Surgery Society and a member of the European Society of Ophthalmic Plastic and Reconstructive Surgeons, the American Academy of Ophthalmology, the European Society of Ophthalmic, Plastic and Reconstructive Surgeons and the Tear Film and Ocular Surface Society. She has published over 20 papers and is a reviewer for many peer-reviewed journals. She has lectured and chaired at many national and international Oculoplastic and Ophthalmology conferences. Oculoplastic surgery is specialised plastic and reconstructive surgery dealing with the eyelids, the tear (lacrimal) system and orbital regions of the face. An Oculoplastic surgeon is an ophthalmologist (medical doctor and eye surgeon) with additional in-depth training and knowledge of the eyelid area. The eyelid and other areas around the eye are delicate structures that need special understanding and care. They not only form a vital part of facial appearance and expression, but are also an important protection for the eyes.

Very often eyelid problems are not just cosmetic but can interfere with visual function, comfort and well-being. An oculoplastic surgeon has the expertise and training to diagnose and treat problems in this complex area. Martin Leyland BSc MD FRCOphth Martin Leyland trained in London, at the Western Eye Hospital and Moorfields Eye Hospital, and was appointed Consultant Ophthalmic Surgeon to the Royal Berkshire Hospital in 2001, and Honorary Consultant at the Oxford Eye Hospital in 2003. Mr Leyland is a specialist in anterior segment disease: cataract, cornea, conjunctiva and lid margin, and leads the corneal service for the Oxford/Berkshire/Buckinghamshire region. Special clinical interests Keratoconus, Fuch's endothelial dystrophy, corneal oedema, herpes simplex keratitis, pterygium. Corneal transplant surgery All types of keratoplasty, including penetrating keratoplasty, deep anterior lamellar keratoplasty, and DSEK endothelial graft surgery.

Mr Leyland is a member of the microsurgical skills faculty of the Royal College of Ophthalmologists, and runs the DSEK course at the surgical skills centre, Royal College of Ophthalmologists, London Dominic McHugh MD MBBS FRCS FRCOphth DO Dominic McHugh qualified at The Middlesex Hospital Medical School following which he underwent specialist training in ophthalmology at St Thomas’ Hospital and then Moorfields Eye Hospital in London. He also undertook a period of research into the applications of semi-conductor diode lasers in ophthalmology, for which he was awarded the degree of Doctor of Medicine by the University of London. He was appointed Consultant Ophthalmic Surgeon at King’s College Hospital in 1994 where he performs vitreoretinal and cataract surgery. He is also actively involved in the management of patients with medical retinal problems such as diabetic retinopathy and age related macular degeneration. He is currently a Referee for ophthalmic papers submitted for publication to the British Medical Journal, the Eye and the British Journal of Ophthalmology. He is a past Assistant Managing Editor of Lasers and Light in Ophthalmology and has previously been on the Editorial Board of the publication Current Medical Literature.

He is currently an Examiner for doctoral theses for the University of London. He has carried out extensive research into ophthalmic application of semi-conductor diode lasers and participated in the development of a portable, semi-conductor diode laser. Since then, he has maintained his interest in semi-conductor lasers, with further publication on the subject. Research has also been performed in a number of areas relating to vitreoretinal surgery, for example alternative methods of retinal reattachment and radiotherapy for macular degeneration. Ali Mearza MBBS FRCOphth Ali Mearza is an NHS Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust, London, the UK's first Academic Health Sciences Centre. He graduated from Charing Cross and Westminster Medical School in 1996 and completed his core ophthalmic training in 2005. Throughout his higher surgical training he developed an interest in cornea and refractive surgery and has completed two corneal fellowships in these fields.

The experience he gained during his first corneal fellowship at Moorfields NHS Trust has given him the groundwork to be at the cutting edge of anterior segment techniques, thus being proficient in complicated cataract surgery, penetrating keratoplasty, deep lamellar keratoplasty, endothelial keratoplasty, sutured intraocular lenses, intraocular lens exchange and iris reconstruction as well as new refractive surgical techniques such as corneal intacs for keratoconus. In his second fellowship he gained experience in refractive surgical techniques including PRK and LASIK, thereby complementing his subspecialty corneal training. To date he has performed over 3000 refractive procedures. As an Ophthalmic Surgeon he is able to deliver a comprehensive modern anterior segment service offering the latest techniques in cornea, cataract and refractive surgery. He has a keen interest in clinical research and has published extensively with over 40 publications to his name including publications in peer reviewed journals, textbooks and media articles.

He has submitted and presented research on numerous occasions both at national and international meetings and he is an invited journal reviewer for Cornea, the British Journal of Ophthalmology, the International Journal of Clinical Practice, International Ophthalmology and Expert Opinion on Drug Safety. He enjoys teaching and continues to teach medical students and GP's basic ophthalmic knowledge and techniques. He also teaches junior colleagues ophthalmic knowledge required for the MRCOphth examinations as well as providing supervision during surgery. He also has a keen interest in voluntary ophthalmology and has performed charitable work in India, Bali, Burma, Madagascar, Bangladesh and Ghana. Danny Morrison BSc (Hons), MBChB, FRCOphth (London), MD. Mr Danny Morrison is a Consultant Ophthalmic Surgeon at Guy's and St. Thomas' NHS Foundation Trust, and at the Evelina Children's Hospital, London. He was appointed in 2005. Mr Morrison trained in Sheffield, Brighton, Leicester, Edinburgh and London. He was a senior specialist registrar at Moorfields Eye Hospital, London, where he also undertook advanced training as a Fellow in ophthalmic plastic surgery.

This was followed by a fellowship in paediatric ophthalmology at Great Ormond Street Children's Hospital and King's College Hospital, London. Mr Morrison did research for the Department of Health on a major study into congenital eye malformations, and wrote his MD thesis with the University of Edinburgh. Mr Morrison has particular expertise in paediatric ophthalmology, children's and adult squints (strabismus), and ophthalmic plastic surgery including ptosis, eyelid lumps and congenital orbital pathology. The paediatric ophthalmology includes assessment for glasses, treatment of amblyopia, vision problems in small babies and children, retinal diseases, as well as common problems such as blocked tear ducts and allergic eye disease. He is also trained in the assessment of all aspects of general ophthalmology, including cataracts and glaucoma. Mr Morrison is a member of The American Academy of Ophthalmology and is a medical advisor to The Eyeless Trust, a charity that supports children born with severe congenital eye abnormalities. He has many publications and international presentations in paediatric ophthalmology, oculoplastics and ocular genetics.

He also reviews articles for Journals such as the British Journal of Ophthalmology and Archives of Ophthalmology. Mr Morrison is undergraduate teaching lead for Ophthalmology at St. Thomas' for King's College Medical School, and is an interview Chair for Admissions to King's Medical School. He also represents the Royal College of Ophthalmologists several times a year at Consultant appointments and Interviews. Paul Rosen BSc(Hons), MB ChB, FRCS, FRCOphth, MBA Paul Rosen completed Medical training at Manchester University before a specialist training at Moorfields Eye Hospital in London. Registered with the General Medical Council as a Specialist in Ophthalmology, Paul Rosen then accepted a position as Consultant Ophthalmic Surgeon at Oxford Eye Hospital in 1993. He was Head of Department from 1998 to 2004 and performs over 1000 cataract/refractive surgical procedures each year between his NHS and private practices. Paul first performed laser refractive surgery in 1991 at Moorfields Eye Hospital and commenced LASIK treatments in 1997.

With a keen interest in education, he is a Senior Lecturer at the University of Oxford and an Examiner for the Royal College of Ophthalmologists for the Certificate in Refractive Surgery. Committed to quality in refractive surgery and valued for his 18 years of experience in laser refractive surgery, Paul was invited to participate on the Royal College of Ophthalmologists Refractive Surgery Working Party. He advises the government's National Institute of Clinical Excellence (NICE). Paul is the past President of the European Society of Cataract and Refractive Surgeons (ESCRS) the largest Society in Europe dedicated to refractive surgery, and past President of the UK and Ireland Society of Cataract and Refractive Surgeons (UKISCRS). He is also a Medical Editor of Eurotimes, a publication of the ESCRS. Paul is regularly invited to lecture on cataract and refractive surgery both nationally and internationally.

Qualifications and Awards Past President European Society of Cataract and Refractive Surgeons (ESCRS) Past President, UK and Ireland Society of Cataract and Refractive Surgeons Registered with the General Medical Council as a Specialist in Ophthalmology Medical Editor, Eurotimes ESCRS magazine Chairman of the Programme and Practice Management Committees of the ESCRS Honour Award recipient from the American Academy of Ophthalmology Royal College of Ophthalmologists Examiner in Refractive Surgery Fellow of the Royal College of Surgeons of Glasgow Fellow of the Royal College of Ophthalmologists Certificate in Refractive Surgery, Royal College of Ophthalmologists Simon Woodruff FRCOphth Mr Woodruff qualified from St Mary's Hospital, London in 1991 and underwent specialist Ophthalmology training in London. This included 4 years of Oculoplastic fellowships at Moorfields Eye Hospital and The Western Eye Hospital during which he received advanced training in plastic, aesthetic and reconstructive surgery of the periocular region and surrounding areas. He has been a Consultant since 2004 and holds NHS Consultant positions at Addenbrookes Hospital, Cambridge where he is the Clinical Director and Moorfields Eye Hospital.

His main area of practice is Ophthalmic Plastic and Reconstructive Surgery including both functional problems, such as periocular tumours, ptosis (droopy upper eyelid), entropion and ectropion and Cosmetic eyelid surgery (blepharoplasty), brow lifts, Botox and facial fillers. He has particular expertise in transconjunctival minimally invasive lower lid blepharoplasty and endoscopic scarless lacrimal (watery eye) surgery. He also performs bespoke small-incision cataract surgery aiming for spectacle independence. Rahila Zakir FRCOphth Rahila Zakir is Consultant Ophthalmologist, Ophthalmic and Vitreoretinal Surgeon at The Western Eye Hospital, part of Imperial College Academic Health Science Centre.

She has a special interest in vitreoretinal conditions such as retinal detachment, macular hole, epiretinal membrane, retinal tears, diabetic retinopathy, vitreous haemorrhage and vitreomacular traction and in medical retinal condition such as Age related macular degeneration, retinal vein occlusion, and all stages of diabetic eye disease from diagnosis and screening for retinopathy, laser and intravitreal injection treatment to vitreoretinal surgery for advanced diabetic eye disease. She is an Eye Accident and Emergency Consultant, and has an interest in eye trauma. She is also experienced in general ophthalmology and cataract surgery. She offers second opinions on retinal surgery management options. She is a committed medical educator and Educational and Clinical Supervisor for Specialty Trainees in Ophthalmology at Western Eye Hospital, Imperial College Healthcare NHS Trust. She provides training in ophthalmology for Specialty Trainees and Vitreoretinal Fellowship training for senior Eye Surgeons. As Associate College Tutor, a Royal College of Ophthalmologists appointment, at the Western Eye Hospital, she supports the team responsible for overseeing the education and training of ophthalmologists.

As Honorary Clinical Senior Lecturer in the Faculty of Medicine, Imperial College London she is actively engaged in the education of medical students. She is also actively engaged in clinical research, and is currently Principal Investigator for studies on Ocriplasmin for vitreomacular traction and macular holes. Previously Clinical Lead for the Age Related Macular Degeneration service at West Suffolk Hospital, Suffolk. Previously clinical lead for the diabetic eye screening service in West Suffolk and later for the East Anglia programme. Completed vitreoretinal fellowship training at Western Eye Hospital and Moorfields Eye Hospital Fellowship training in full range of vitreoretinal conditions, including complex retinal detachments, advanced diabetic eye disease, major eye trauma and paediatric vitreoretinal conditions Medical retina fellowship training at Moorfields Eye Hospital Fellowship training in medical retinal conditions including diabetic retinopathy, macular degeneration, uveitis, retinal vascular diseases including retinal vein occlusion and sickle cell retinopathy, macular disease. Ophthalmology Specialist Registrar training rotation, including, previous to this, Kings College Hospital, London, West Kent Hospital, Farnborough and West Suffolk Hospital, Bury St Edmunds, Suffolk.

Hadi Zambarakji DM, FRCOphth Hadi Zambarakji was appointed as Consultant Ophthalmic Surgeon at Whipps Cross University Hospital NHS Trust in 2005. He was a fellow in Vitreoretinal surgery at Moorfields Eye Hospital (2002-2004), and in Medical Retina at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston (2004-2005). He is currently Regional Advisor for the Royal College of Ophthalmologists for the North East Thames region. He has a strong interest in education and training, having previously been College Tutor for the Royal College of Ophthalmologists, and having developed the post-graduate educational program in Ophthalmology at Whipps Cross. His clinical interests include vitreoretinal and small incisional cataract surgery, as well as medical retina. This includes diseases and surgery of the retina and vitreous (retinal detachment surgery), diabetic eye disease, retinal vascular disease and macular degeneration.

His research interests include imaging in retinal disorders, vitreomacular diseases, macular holes, diabetic macular oedema, investigational treatments for diabetic retinopathy and macular degeneration, and angiogenesis. He has taken an active role in research throughout his training and continues to do so as a Consultant. He takes an active role in training young ophthalmologists and runs a Vitreoretinal Fellowship Training Programme. Orthoptists Carolyn Calcutt DBO(D) FBIOS ORTHOPTIST Carolyn trained at Moorfields Eye Hospital, and spent her first years as an orthoptist running four hospital departments in Kent. She returned to London to work with Eric Arnott firstly at Royal Eye Hospital, then at the new Charing Cross Hospital where she was Head Orthoptist for over 30 years. She was Chairman of British Orthoptic Society from 1974 until 1981 and following that represented UK on Council of International Orthoptic Association. She has undertaken a considerable amount of clinical research, has lectured all over the world and has published more than 40 papers.

In 1991 she was awarded the accolade of being the Burian Lecturer at International Orthoptic Conference in Germany, and in 1992 gave Patricia Lance Lecture at the annual meeting of Orthoptic Association of Australia. She has been a Guest Fellow at both Sydney and La Trobe Universities in Australia. In 1997 she was awarded a Fellowship by British and Irish Orthoptic Society for her services to orthoptics. Special interests: All aspects of adult and paediatric strabismus and the diagnosis and management of defects affecting binocular vision. Connam Tam MCOptom BSc(Hons)Orthoptics Optometrists Raj Bharaj BSc MCOptom Rajinder Bharaj (Raj) graduated from The City University with an honours degree and prize in clinical practice in Optometry in 1997. She continued her training with an independent practice with close links to Moorfields Eye Hospital and The Institute of Optometry. She gained valuable experience working in a low vision hospital clinic and seeing patients under domiciliary conditions.Raj has also undertaken a tandem parachute jump with the Red Devils in support of the RNIB.

Having worked for various independent practices Raj went on to successfully open up her own practice in the east end of London. Raj's main area of interest is retinal eye disease and has been associated with Arnott Eye Associates for over four years. Puja Sheena Shah BSc(Hons) MCOptom Puja Sheena Shah graduated in Optometry from City University, London in 2004 and subsequently received her professional qualification exams whilst working at a busy flagship on Oxford Street, London. After Qualification in 2005 she was able to give back to the profession by mentoring the latest graduates at the Institute of Optometry. She has also been involved with supervising the final year students at City University. This included ensuring all core competencies from the General Optical Council were completed to a high standard before allowing them to graduate. Puja has worked for a large variety of high street opticians in many different areas in and around London. This experience has led her to her main areas of interest; Contact Lenses. Puja is an active member of the British Contact Lens Association and obtained much of her continued education credits from advances in Contact Lenses whilst studying for an advanced diploma in contact lenses.

Puja's continued mix of work in the academic, retail and medical sectors has allowed her to uniquely position herself to provide the very best optical care for our patients. Cosmetic Treatments & Plastic Surgery London | The McIndoe Centre Back to Consultants Listing MB.ChB,FRCOphth Mr Damian Lake is a Consultant Ophthalmologist, Corneal and Refractive Surgeon. He is accredited in all aspects of eye care but specialises in Corneal transplantation, Cataract and Laser Refractive surgery, Stem cell surgery and reconstruction of damaged eyes. After graduating in Medicine and Surgery from The University of Glasgow, Mr Lake completed Ophthalmic surgical training in London before completing two Corneal fellowship positions, first at Moorfields Hospital and then at The Queen Victoria Hospital East Grinstead, where he was subsequently appointed as a Consultant and Medical advisor to the Eye Bank.

Mr Lake is a Fellow of The Royal College of Ophthalmologists, member of The American Academy of Ophthalmologists,United Kingdom and Ireland Society of Cataract and Refractive Surgeons, European Society of Cataract and Refractive Surgeons, The Cornea Society and Chairman of the Ocular tissue and Transplantation Standards Group of the Royal College of Ophthalmologists. Mr Lake is dedicated to providing a caring service with attention to detail and exemplary outcomes. Arrange consultation The McIndoe Centre is regulated by the Care Quality Commission to provide care The McIndoe Centre, part of Horder Healthcare Holtye Road West Sussex, RH19 3EB, UK. Registered Charity No. 1046624

Question: Moorfield’s Hospital in London specialises in the treatment of which part of the body?
Answer: Eyes